<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>24913991</identifier>
<setSpec>1578-1852</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Pericas, Juan Manuel</dc:author>
<dc:author>Letang, Emili</dc:author>
<dc:author>Bastida, Carla</dc:author>
<dc:author>Also, Maria Antonia</dc:author>
<dc:author>Miró, Josep Maria</dc:author>
<dc:author>Tuset, Montse</dc:author>
<dc:description xml:lang="en">INTRODUCTION Drugs like statins may induce rhabdomyolysis. Simvastatin and lovastatin have a high hepatic metabolism and their potential toxicity could be increased by interactions with other drugs that reduce their metabolism. PATIENTS AND METHODS A case-report is presented of an HIV-infected patient treated with antiretroviral drugs who developed a rhabdomyolysis-induced renal failure and liver toxicity when simvastatin was substituted for atorvastatin. A literature review is also presented. RESULTS The patient required hospital admission and showed a favorable response after hydration and urine alkalinization. There were 4 additional cases published of which there was one death. CONCLUSIONS Drug-drug interactions can increase the risk of statin induced rhabdomyolysis. In order to evaluate them properly, physicians at all levels of clinical care should be aware of all drugs prescribed to their patients and the contraindicated combinations.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:subject>Antiretroviral drugs</dc:subject>
<dc:subject>Tratamiento antirretroviral</dc:subject>
<dc:subject>Ritonavir</dc:subject>
<dc:subject>Simvastatin</dc:subject>
<dc:subject>Inhibidores de la hidroximetilglutaril-coA reductasa</dc:subject>
<dc:subject>Hydroxymethylglutaryl-CoA reductase inhibitors</dc:subject>
<dc:subject>Rhabdomyolysis</dc:subject>
<dc:subject>Rabdomiólisis</dc:subject>
<dc:subject>Simvastatina</dc:subject>
<dc:subject>Estatinas</dc:subject>
<dc:subject>Renal failure</dc:subject>
<dc:subject>Drug-drug interactions</dc:subject>
<dc:subject>Interacciones medicamentosas</dc:subject>
<dc:subject>Human immunodeficiency virus</dc:subject>
<dc:subject>Insuficiencia renal</dc:subject>
<dc:subject>Virus de la inmunodeficiencia humana</dc:subject>
<dc:subject>Hepatotoxicity</dc:subject>
<dc:subject>Statins</dc:subject>
<dc:subject>Hepatotoxicidad</dc:subject>
<dc:date>2014 Nov </dc:date>
<dc:title xml:lang="es">Rabdomiólisis y hepatotoxicidad grave por interacción entre ritonavir y simvastatina. ¿Puede emplearse la estatina más coste-efectiva en todos los pacientes infectados por el virus de la inmunodeficiencia humana?</dc:title>
<dc:title xml:lang="en">[Rhabdomyolysis and severe hepatotoxicity due to a drug-drug interaction between ritonavir and simvastatin. Could we use the most cost-effective statin in all human immunodeficiency virus-infected patients?].</dc:title>
<dc:publisher>Enfermedades infecciosas y microbiologia clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
